Target Poor or Non Binder(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T48598 | Target Info | |||
| Target Name | GTPase KRas (KRAS) | ||||
| Synonyms |
c-Ki-ras; c-K-ras; RASK2; Ki-Ras; KRAS2; K-Ras 2
Click to Show/Hide
|
||||
| Target Type | Clinical trial Target | ||||
| Gene Name | KRAS | ||||
| Biochemical Class | Small GTPase | ||||
| UniProt ID | |||||
| Poor Binders of This Target (in total, 6 binders) | Download | Top | |||
|---|---|---|---|---|---|
| Compound Name |
[(2R,3S,4R,5R)-5-(2-Amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[[[(1R,3S)-3-[(2-chloroacetyl)amino]cyclopentyl]oxy-hydroxyphosphoryl]methyl]phosphinic acid
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL3945018; BDBM50501346
Click to Show/Hide
|
||||
| Activity |
Ki = 50000 nM
|
[1] | |||
| Compound Name |
(S)-1-(4-(6-Chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
ARS-1620; ARS-1323; ARS-1630; CHEMBL4214264; ARS-1323 (racemic); ARS-1620 (S-configuration); ARS-1630 (R-configuration); SCHEMBL16637284; GTPL10383; ARS1323; ARS1620; ARS 1323; BCP29127; EX-A2714; EX-A2836; EX-A2837; BDBM50459706; HY-U00416; s8707; example 227 [US9840516B2]; ACN-053846; ACN-053847; ACN-053848; SB23244; AC-31602; AC-31607; AC-31608; BS-15572; CS-0035015; A16809
Click to Show/Hide
|
||||
| Activity |
Ki ~ 64000 nM
|
[2] | |||
| Compound Name |
(3R,8R,11S,14S,20S,23S,26S,29S,32S,35S,38S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-Acetamido-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-29-[(2S)-butan-2-yl]-26-(hydroxymethyl)-23,32-bis[(4-hydroxyphenyl)methyl]-20-methyl-35-(2-methylpropyl)-2,10,13,19,22,25,28,31,34,37-decaoxo-11-propan-2-yl-5,6-dithia-1,9,12,18,21,24,27,30,33,36-decazatricyclo[36.3.0.014,18]hentetracontane-8-carboxamide
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL4074790; BDBM50242351
Click to Show/Hide
|
||||
| Activity |
IC50 = 65000 nM
|
[3] | |||
| Compound Name |
2-[(3R,8R,11S,14S,20S,23S,26S,29S,32S,35S,38S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-Acetamido-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-8-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-26-(hydroxymethyl)-23,32-bis[(4-hydroxyphenyl)methyl]-29-methyl-35-(2-methylpropyl)-2,10,13,19,22,25,28,31,34,37-decaoxo-11-propan-2-yl-5,6-dithia-1,9,12,18,21,24,27,30,33,36-decazatricyclo[36.3.0.014,18]hentetracontan-20-yl]acetic acid
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL4075783; BDBM50242350
Click to Show/Hide
|
||||
| Activity |
IC50 = 73500 nM
|
[3] | |||
| Compound Name |
2-[(3R,8R,11S,14S,20S,23S,26S,29S,32S,35S,38S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-Acetamido-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-8-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-29-[(2S)-butan-2-yl]-26-(hydroxymethyl)-23,32-bis[(4-hydroxyphenyl)methyl]-35-methyl-2,10,13,19,22,25,28,31,34,37-decaoxo-11-propan-2-yl-5,6-dithia-1,9,12,18,21,24,27,30,33,36-decazatricyclo[36.3.0.014,18]hentetracontan-20-yl]acetic acid
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
CHEMBL4084139; BDBM50242328
Click to Show/Hide
|
||||
| Activity |
IC50 ~ 100000 nM
|
[3] | |||
| Compound Name |
2-(4,6-Dichloro-2-methyl-1H-indol-3-yl)ethanamine
Click to Show/Hide
|
Investigative | Compound Info | ||
| Synonyms |
2-(4,6-Dichloro-2-methyl-1H-indol-3-yl)-ethylamine; 4,6-Dichloro-2-methyl-1H-indole-3-ethanamine; CHEMBL2396992; MFCD02656500; 2-(4,6-dichloro-2-methyl-1H-indol-3-yl)ethan-1-amine; Oprea1_501186; SCHEMBL16246781; AOB2881; DCAI, >=95% (HPLC); ZINC1235017; 1126AJ; BBL014412; BDBM50436053; STK056172; AKOS005386598; SB36455; AC-30470; AS-16733; SY096641; 4,6-Dichloro-2-methyl-3-aminoethylindole; 4,6-dichloro-2-methyl-3-aminoethyl-indole; BB 0259655; H4154; Q27457025; 2-(4,6-dichloro-2-methyl-1H-indol-3-yl)-1-ethanamine; 2-(4,6-dichloro-2-methyl-1H-indol-3-yl)ethanamine, AldrichCPR
Click to Show/Hide
|
||||
| Activity |
IC50 = 155000 nM
|
[4] | |||
| Click to Show/Hide the Information of All Poor Binders | |||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Med Chem Lett. 2016 Nov 30;8(1):61-66. | ||||
| REF 2 | Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. ACS Med Chem Lett. 2018 Aug 2;9(9):861-3. | ||||
| REF 3 | Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2757-2761. | ||||
| REF 4 | Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. Bioorg Med Chem Lett. 2015 Jun 15;25(12):2461-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.